Technical Analysis for NRIX - Nurix Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 22.05 | -1.43% | -0.32 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Spinning Top | Other | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Calm After Storm | Range Contraction | -1.43% | |
| Wide Bands | Range Expansion | -1.43% | |
| Oversold Stochastic | Weakness | -1.43% |
| Alert | Time |
|---|---|
| Possible NR7 | about 15 hours ago |
| 60 Minute Opening Range Breakout | about 19 hours ago |
| Fell Below Previous Day's Low | about 19 hours ago |
| Down 2 % | about 19 hours ago |
| Down 1% | about 19 hours ago |
Get a Trading Assistant
- Earnings date: 10/10/2024
Nurix Therapeutics, Inc. Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications. It also provides DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a class of enzymes that could modulate proteins within the cell. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc.; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was founded in 2009 and is headquartered in San Francisco, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Treatment Of Cancer Lymphoma Enzymes Tyrosine Kinase Immune Disorders Small Molecule Therapies Gilead Sciences Oncogene Bruton's Tyrosine Kinase
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 29.56 |
| 52 Week Low | 5.68 |
| Average Volume | 909,381 |
| 200-Day Moving Average | 19.02 |
| 50-Day Moving Average | 24.37 |
| 20-Day Moving Average | 25.03 |
| 10-Day Moving Average | 24.37 |
| Average True Range | 1.51 |
| RSI (14) | 37.50 |
| ADX | 24.22 |
| +DI | 19.01 |
| -DI | 31.53 |
| Chandelier Exit (Long, 3 ATRs) | 25.04 |
| Chandelier Exit (Short, 3 ATRs) | 25.17 |
| Upper Bollinger Bands | 29.05 |
| Lower Bollinger Band | 21.01 |
| Percent B (%b) | 0.13 |
| BandWidth | 32.14 |
| MACD Line | -0.57 |
| MACD Signal Line | 0.01 |
| MACD Histogram | -0.5748 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 23.33 | ||||
| Resistance 3 (R3) | 23.36 | 22.98 | 23.11 | ||
| Resistance 2 (R2) | 22.98 | 22.65 | 22.96 | 23.04 | |
| Resistance 1 (R1) | 22.51 | 22.45 | 22.32 | 22.48 | 22.97 |
| Pivot Point | 22.13 | 22.13 | 22.03 | 22.11 | 22.13 |
| Support 1 (S1) | 21.66 | 21.80 | 21.47 | 21.63 | 21.13 |
| Support 2 (S2) | 21.28 | 21.60 | 21.26 | 21.06 | |
| Support 3 (S3) | 20.81 | 21.28 | 20.99 | ||
| Support 4 (S4) | 20.78 |
